STOCK TITAN
  1. Home
  2. Sec-filings
  3. MPLT
  4. [Form 4] MapLight Therapeutics, Inc. Insider Trading Activity

MapLight Therapeutics (MPLT) CDO sells 36K shares via tax and plan trades

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. reporting person Anatol Kreitzer, Chief Discovery Officer, reported selling 36,284 shares of Voting Common Stock from July 15–17, 2026 at weighted-average prices, with underlying trade prices ranging from $35.68 to $38.21 per share. Sales on July 15–16 covered statutory tax withholding from vesting restricted stock units via mandated “sell to cover” transactions, while July 17 sales were executed pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. Following these transactions, Kreitzer directly held 174,906 shares of Voting Common Stock.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Kreitzer Anatol
Role Chief Discovery Officer
Sold 36,284 shs ($1.35M)
Type Security Shares Price Value
Sale Voting Common Stock F6, F7 2,833 $37.05 $105K
Sale Voting Common Stock F6, F8 14,140 $37.70 $533K
Sale Voting Common Stock F6 200 $38.39 $8K
Sale Voting Common Stock F1, F4 7,464 $36.66 $274K
Sale Voting Common Stock F1, F5 1,592 $37.44 $60K
Sale Voting Common Stock F1, F2 5,545 $36.13 $200K
Sale Voting Common Stock F1, F3 4,510 $36.94 $167K
Holdings After Transaction: Voting Common Stock — 174,906 shares (Direct)
Footnotes (8)
  1. F1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.68 to $37.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.12 to $37.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $37.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025.
  7. F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.36 to $37.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 36,284 shares Aggregate Voting Common Stock sales reported from July 15–17, 2026
Sale price range $35.68–$38.21 per share Trade price ranges disclosed in weighted-average price footnotes F2–F5, F7–F8
Holdings after transactions 174,906 shares Direct Voting Common Stock held by Anatol Kreitzer following the latest reported sale
Largest single reported sale 14,140 shares at $37.70 per share Voting Common Stock sale dated July 17, 2026 with weighted-average price
Rule 10b5-1 trading plan regulatory
"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
restricted stock units financial
"in connection with the vesting of the restricted stock units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
statutory tax withholding obligations financial
"to cover the statutory tax withholding obligations in connection with the vesting..."
"sell to cover" transaction financial
"to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction..."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →

FAQ

What insider share sales did MapLight Therapeutics (MPLT) disclose for Anatol Kreitzer?
Anatol Kreitzer reported selling 36,284 shares of MapLight Therapeutics Voting Common Stock between July 15 and July 17, 2026. The trades combined tax-related “sell to cover” transactions tied to vesting RSUs and additional sales made under a Rule 10b5-1 trading plan.

How many MPLT shares does Anatol Kreitzer hold after the reported Form 4 transactions?
After the reported sales, Anatol Kreitzer directly holds 174,906 shares of MapLight Therapeutics Voting Common Stock. This figure comes from the post-transaction holding amount disclosed for the most recent transaction included in the Form 4 filing for July 2026.

At what prices were the MPLT shares sold by Anatol Kreitzer in July 2026?
The reported per-share prices are weighted averages, such as $36.13, $36.94, $36.66, $37.44, $37.05, $37.70 and $38.39. Footnotes state that individual trades occurred within ranges from $35.68 up to $38.21 per share across the different sale transactions.

What does the Rule 10b5-1 trading plan reference mean in MPLT’s Form 4?
The Form 4 notes that certain July 17, 2026 sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. This indicates those trades followed a pre-established plan described in the footnote rather than being timed on an ad hoc basis.

Which MPLT transactions were identified as tax “sell to cover” trades for Anatol Kreitzer?
Four sales on July 15 and July 16, 2026 carry a footnote stating they represent shares required to be sold to cover statutory tax withholding obligations related to vesting restricted stock units, and that these mandated “sell to cover” sales are not discretionary.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kreitzer Anatol
(Last)(First)(Middle)
C/O MAPLIGHT THERAPEUTICS, INC.
800 CHESAPEAKE DRIVE
(Street)
REDWOOD CITY CALIFORNIA 94063
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MPLT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Discovery Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Voting Common Stock07/15/2026S(1)5,545(1)D$36.13(2)205,645D
Voting Common Stock07/15/2026S(1)4,510(1)D$36.94(3)201,135D
Voting Common Stock07/16/2026S(1)7,464(1)D$36.66(4)193,671D
Voting Common Stock07/16/2026S(1)1,592(1)D$37.44(5)192,079D
Voting Common Stock07/17/2026S(6)2,833(6)D$37.05(7)189,246D
Voting Common Stock07/17/2026S(6)14,140(6)D$37.7(8)175,106D
Voting Common Stock07/17/2026S(6)200(6)D$38.39174,906D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.68 to $36.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.68 to $37.325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.12 to $37.11 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $37.70 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 24, 2025.
7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.36 to $37.335 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.21 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Kristopher L. Hanson, Attorney-in-Fact07/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR